The World of Dementia Beyond 2020

Journal of the American Geriatrics Society - Tập 59 Số 5 - Trang 923-927 - 2011
Henry Brodaty1,2,3,4,5,6,7,8, Monique M.B. Breteler1,2,3,4,5,6,7,8, Steven T. DeKosky1,2,3,4,5,6,7,8, Pascale Dorenlot1,2,3,4,5,6,7,8, Laura Fratiglioni1,2,3,4,5,6,7,8, Christoph Höck1,2,3,4,5,6,7,8, Paul-Ariel Kenigsberg1,2,3,4,5,6,7,8, Philip Scheltens1,2,3,4,5,6,7,8, Bart De Strooper1,2,3,4,5,6,7,8
1Division of Psychiatry Research, University of Zürich, Zurich, Switzerland
2From the *Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia
3§Studies Department and **Economics, Finance and Prospective, Fondation Médéric Alzheimer, Paris, France
4†Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
5Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
6School of Medicine, University of Virginia, Charlottesville, Virginia
7‡‡Center for Human Genetics, KU Leuven, and Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium.
8∥Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ferri, 2005, Global prevalence of dementia, A Delphi consensus study, 366, 2112

2009, World Alzheimer Report

Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease, Revising the NINCDS-ADRDA criteria, 6, 734

Fratiglioni, 2004, An active and socially integrated lifestyle in late life might protect against dementia, Lancet Neurol, 3, 343, 10.1016/S1474-4422(04)00767-7

Breteler, 2000, Vascular risk factors for Alzheimer's disease, An epidemiologic perspective, 21, 153

Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement, 3, 186, 10.1016/j.jalz.2007.04.381

Andrieu, 2009, Methodological issues in primary prevention trials for neurodegenerative dementia, J Alzheimers Dis, 16, 235, 10.3233/JAD-2009-0971

Mangialasche, 2010, Alzheimer's disease, Clinical trials and drug development, 9, 702

Selkoe, 2002, Alzheimer's disease is a synaptic failure, Science, 298, 789, 10.1126/science.1074069

Annaert, 2002, A cell biological perspective on Alzheimer's disease, Annu Rev Cell Dev Biol, 18, 25, 10.1146/annurev.cellbio.18.020402.142302

Hebert, 2007, Molecular biology. miRNAs in neurodegeneration, Science, 317, 1179, 10.1126/science.1148530

Kosik, 2006, The neuronal microRNA system, Nat Rev Neurosci, 7, 911, 10.1038/nrn2037

Mahley, 2009, Apolipoprotein E, Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS, 50, S183

Bayer, 2005, Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD, Neurology, 64, 94, 10.1212/01.WNL.0000148604.77591.67

Gilman, 2005, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 64, 1553, 10.1212/01.WNL.0000159740.16984.3C

Orgogozo, 2003, Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, 61, 46, 10.1212/01.WNL.0000073623.84147.A8

Holmes, 2008, Long-term effects of Abeta42 immunisation in Alzheimer's disease, Follow-up of a randomised, placebo-controlled phase I trial, 372, 216

Tuszynski, 2005, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease, Nat Med, 11, 551, 10.1038/nm1239

Neuropathology Group., 2001, Medical Research Council Cognitive F, Aging S. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), Lancet, 357, 169, 10.1016/S0140-6736(00)03589-3

Viswanathan, 2009, Vascular risk factors and dementia, How to move forward?, 72, 368

Vickland, 2010, A computer model of dementia prevalence in Australia, Foreseeing outcomes of delaying dementia onset, slowing disease progression, and eradicating dementia types, 29, 123

Wimo, 2007, An estimate of the total worldwide societal costs of dementia in 2005, Alzheimers Dement, 3, 81, 10.1016/j.jalz.2007.02.001

World Health Organization. http://www.who.int/whr/2008/en/index.html

Thông tin
Thông tin xuất bản

Journal of the American Geriatrics Society

Tập 59 Số 5

923-927

Thông tin tác giả